Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Inclusion Criteria:

• Established diagnosis of hypertriglyceridemia (HTG) and prior documented evidence (medical history) of mean fasting TG level ≥150 mg/dL (≥1.69 mm/L) and ≤499 mg/dL (≤5.64 mmol/L)

• Mean fasting TG level ≥150 mg/dL (≥1.69 mmol/L) and ≤499 mg/dL (≤5.64 mmol/L)collected at 2 separate and consecutive visits at least 7 days apart and no morethan 17 days apart during the screening period

• Fasting low density lipoprotein-cholesterol (LDL-C) ≤ 130 mg/dL (≤3.37 mmol/L) atscreening

• Screening HbA1c ≤9%

• Willing to follow diet counseling and maintain a stable low-fat diet

• Must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant as determined by the Investigator, including aninability to safely administer or re-administer a specific drug because of fear,preference, genetic, clinical, or metabolic considerations, or due a previousadverse reaction associated with, attributed to, or caused by specific drug) priorto collection of qualifying TG levels.

Exclusion Criteria:

• Use of any hepatocyte-targeted small interfering ribonucleic acid (siRNA) thattargets lipids and/or triglycerides within 365 days before Day 1 (except inclisiran,which is permitted). Administration of investigational drug and inclisiran must beseparated by at least 4 weeks.

• Use of any other hepatocyte targeted siRNA or antisense Oligonucleotide moleculewithin 60 days or within 5-half-lives before Day 1 based on plasma pharmacokinetics (PK), whichever is longer

• Acute pancreatitis within 4 weeks prior to screening

• Body mass index >45 kg/m^2

Note: Additional Inclusion/Exclusion criteria may apply per protocol